• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

DNA - Articles and news items

How to get the best out of your high pressure homogeniser

How to get the best out of your high pressure homogeniser

Supplier news / 5 September 2016 / Biopharma Group

Fluid processing requirements are becoming ever more stringent, and so high pressure homogenisation is increasingly surfacing as a solution to meeting these needs…


High throughput single cell applications set to benefit from Dolomite’s novel µEncapsulator 1 System

Supplier news / 16 December 2015 / Dolomite

Dolomite, a world leader in microfluidics innovation, has launched the groundbreaking µEncapsulator 1 System, the only microfluidic product specifically designed to meet the needs of research biologists…

NEB® launches new NEBNext® Ultra™ II Kit for NGS Library Preparation with as little as 500 pg of input DNA

NEB® launches new NEBNext® Ultra™ II Kit for NGS Library Preparation with as little as 500 pg of input DNA

Supplier news / 4 November 2015 / New England BioLabs, Inc.

New Ultra II technology addresses lower input amounts and challenging sample types for Illumina® next generation sequencing systems…

New Lymphocyte Genome Sensitivity assay can potentially identify patients with any cancer

New Lymphocyte Genome Sensitivity assay can potentially identify patients with any cancer

Supplier news / 17 September 2015 / Andor

Andor Komet software characterises ‘Comets’ to detect Cancer…

PCR Viability

Viability PCR – the next level in PCR-based pathogen testing

Industry news, Webinars / 19 November 2014 / Dr. Marcia Armstrong

This pharma webinar introduces Viability PCR as a fast and powerful tool to analyze food samples for the presence of potentially harmful microbes.


DNA in ‘gene deserts’ linked with breast cancer

Industry news / 23 September 2014 / The Institute of Cancer Research

Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports…

FIGURE 1 The rapid evolution of sequencing technologies. A. First generation Sanger sequencing technology. B. Second ‘Next’ generation massively parallel sequencing technology (454 Sequencing © Roche Diagnostics) C. Third ‘Next-Next’ generation single molecule, real-time sequencing technology. In the coming years, second or third generation technologies may develop to an extent where a human genome can be sequenced for a USD 1,000 in a matter of hours

DNA sequencing technologies and emerging applications in drug discovery

Genomics, Issue 6 2011 / 13 December 2011 / Nalini A.L. Mehta & David J. Dow, Molecular and Cellular Technologies, Platform Technology and Science, GlaxoSmithKline and Anthony M. Battram, Molecular and Cellular Technologies, Platform Technology and Science, GlaxoSmithKline & Department of Life Sciences, Imperial College London

In recent years, the development of Next Generation DNA Sequencing (NGS) technology has significantly impacted molecular biology research, resulting in many new insights and discoveries. NGS technology goes beyond traditional DNA sequencing with applications that reach across the central dogma of molecular biology from DNA to RNA and protein science. Drug discovery is beginning to benefit from the diversity of NGS, with applications in evidence across various therapeutic areas, such as oncology, immunology and infectious diseases.

DNA is the molecule of life, containing the information for the synthesis of RNA molecules and proteins, which in turn form structural components of the cell or catalyse essential biochemical processes. Understanding the sequence of DNA, which is made from the four basic building blocks or ‘nucleotides’, A,G,C and T, has resulted in great insights and discoveries in cellular biology, pathology and disease, culminating in the human genome project, which achieved the remarkable feat of determining the sequence of the three billion bases of the human genome.

The field of DNA sequencing has witnessed some key milestones in technology develop – ment since the description of the first revolutionary DNA sequencing techniques in 19771,2. The Sanger dideoxy sequencing method, discovered by the Nobel Laureate Fred Sanger, underwent the most significant improvements and became the first automated sequencing platform in the late 20th century. Advancements in the Sanger process were partly motivated by the advent of the USD 3 billion Human Genome Project, which required the development of high-throughput tech – niques3,4 (Figure 1A).

PCR Viability

PCR and personalised cancer medicine

Genomics, Issue 6 2010 / 16 December 2010 / Frank McCaughan, MRC Career Development Fellow, MRC Laboratory of Molecular Biology

The delivery of personalised medicine is a key goal of modern cancer medicine and refers to the tailoring of anticancer therapy to the molecular characteristics of an individual tumour. To facilitate personalised medicine, it is important to have robust and reproducible means of gaining molecular information about a patient’s cancer that can be used to guide clinical decision-making. There have therefore been tremendous efforts to identify molecular signatures – biomarkers – that can be used to help predict a cancer patient’s prognosis or their likelihood of a response to targeted drug therapies. Such molecular profiling has long been applied to haematological malignancies and is increasingly becoming the norm in the most common epithelial cancers such as lung and colorectal cancer. This article will focus on the role of the polymerase chain reaction (PCR) in helping to meet the challenges involved in the design, testing and delivery of personalised cancer medicine.

Figure 1 Advances in the development of sequencing technologies have resulted in an increase in data output with a dramatic decrease in cost. This graph compares calculated sequencing costs for one complete haploid human genome sequence (23 chromosomes, three billion bases) * estimated from literature ** marketing figures

The Sequencing Revolution: enabling personal genomics and personalised medicine

Genomics, Issue 5 2010 / 29 October 2010 / Bhupinder Bhullar, Novartis Institute for Biomedical Research

It has been 10 years since the completion of the first draft of the human genome. Today, we are in the midst of a full assault on the human genetic code, racing to uncover the genetic mechanisms that affect disease, aging, happiness, violence … and just about every imaginable human variation. Advances in DNA sequencing technology have enabled individuals to have their own genomes sequenced rapidly, cheaply and in astonishing detail. The sequencing revolution is also changing the way the pharmaceutical industry develops, tests and targets new medicines.


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +